GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RxSight Inc (NAS:RXST) » Definitions » Cash, Cash Equivalents, Marketable Securities

RxSight (RxSight) Cash, Cash Equivalents, Marketable Securities : $125.4 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is RxSight Cash, Cash Equivalents, Marketable Securities?

RxSight's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($131.88 Mil) to Dec. 2023 ($127.18 Mil) but then stayed the same from Dec. 2023 ($127.18 Mil) to Mar. 2024 ($125.35 Mil).

RxSight's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($159.33 Mil) to Dec. 2022 ($105.80 Mil) but then increased from Dec. 2022 ($105.80 Mil) to Dec. 2023 ($127.18 Mil).


RxSight Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for RxSight's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RxSight Cash, Cash Equivalents, Marketable Securities Chart

RxSight Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
80.67 68.98 159.33 105.80 127.18

RxSight Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.94 147.09 131.88 127.18 125.35

RxSight Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


RxSight  (NAS:RXST) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


RxSight Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of RxSight's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


RxSight (RxSight) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RxSight Inc (NAS:RXST) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
Executives
Ilya Goldshleger officer: Chief Operating Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric Weinberg officer: Chief Commercial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Jesse Anderson Corley director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Kurtz Ronald M Md director, officer: See Remarks C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shelley B Thunen officer: Chief Financial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Bakker Juliet Tammenoms director LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert J Palmisano director 110 HARTWELL AVENUE, LEXINGTON MA 02173
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Julie Andrews director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116